However, with few exceptions, the stem cell and regenerative medicine industry has remained inadequately capitalized to carry out large - scale clinical trials independently, and
major pharmaceutical firms have tended to show more
interest in the use of hiPSCs as a source of large, pure populations of specific somatic cells for use in drug compound screening and toxicology tests, than they have in
therapeutic uses of stem cells and their derivatives.